Table 3.
Adverse events of anti-SARS-CoV-2 vaccination schedule within 84 days after boost dose.
| Group 1 (n = 100) |
Group 2 (n = 100) |
Group 3 (n = 100) |
Group 4 (n = 99) |
P-value | ||
|---|---|---|---|---|---|---|
| Pain, n (%) | Yes | 62 (62.0%) | 74 (74.0%) | 96 (96.0%) | 94 (94.9%) | <0.001 |
| Grade 2 or 3 | 14 (14.0%) | 50 (50.0%) | 44 (44.0%) | 40 (40.4%) | <0.001 | |
| Grade 3 | 2 (2.0%) | 15 (15.0%) | 9 (9.0%) | 3 (3.0%) | 0.001 | |
| Erythema, n (%) | Yes | 7 (7.0%) | 14 (14.0%) | 23 (23.0%) | 17 (17.2%) | 0.016 |
| Swelling, n (%) | Yes | 6 (6.0%) | 25 (25.0%) | 42 (42.0%) | 23 (23.2%) | <0.001 |
| Fever, n (%) | Yes | 8 (8.0%) | 32 (32.0%) | 55 (55.0%) | 42 (42.4%) | <0.001 |
| Chills, n (%) | Yes | 16 (16.0%) | 50 (50.0%) | 51 (51.0%) | 41 (41.1%) | <0.001 |
| Grade 2 or 3 | 4 (4.0%) | 20 (20.0%) | 28 (28.0%) | 12 (12.1%) | <0.001 | |
| Grade 3 | 1 (1.0%) | 4 (4.0%) | 0 (0.0%) | 0 (0.0%) | 0.034 | |
| Headache, n (%) | Yes | 30 (30.0%) | 54 (54.0%) | 53 (53.0%) | 42 (42.4%) | 0.002 |
| Grade 2 or 3 | 8 (8.0%) | 22 (22.0%) | 26 (26.0%) | 17 (17.2%) | 0.007 | |
| Grade 3 | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | 1 (1.0%) | 1.000 | |
| Myalgia, n (%) | Yes | 46 (46.0%) | 68 (68.0%) | 91 (91.0%) | 87 (87.9%) | <0.001 |
| Grade 2 or 3 | 9 (9.0%) | 39 (39.0%) | 33 (33.0%) | 26 (26.3%) | <0.001 | |
| Grade 3 | 1 (1.0%) | 6 (6.0%) | 1 (1.0%) | 2 (2.0%) | 0.074 | |
| Fatigue, n (%) | Yes | 55 (55.0%) | 69 (69.0%) | 91 (91.0%) | 84 (84.8%) | <0.001 |
| Grade 2 or 3 | 13 (13.0%) | 42 (42.0%) | 30 (30.0%) | 28 (28.3%) | <0.001 | |
| Grade 3 | 2 (2.0%) | 4 (4.0%) | 1 (1.0%) | 3 (3.0%) | 0.560 | |
| Rashes, n (%) | Yes | 5 (5.0%_ | 11 (11.0%) | 8 (8.0%) | 6 (6.1%) | 0.393 |
| Grade 2 or 3 | 1 (1.0%) | 5 (5.0%) | 4 (4.0%) | 4 (4.0%) | 0.445 | |
| Generalized rashes, n (%) | Yes | 0 (0.0%) | 2 (2.0%) | 1 (1.0%) | 1 (1.0%) | 0.569 |
| Arthralgia/arthritis, n (%) | Yes | 1 (1.0%) | 11 (11.0%) | 12 (12.0%) | 7 (7.1%) | 0.015 |
| GI upset (nausea/vomit), n (%) | Yes | 2 (2.0%) | 7 (7.0%) | 8 (8.0%) | 5 (5.1%) | 0.259 |
| Others, n (%) | Yes | 10 (10.0%) | 21 (21.0%) | 19 (19.0%) | 19 (19.2%) | 0.162 |
Others include chest tightness (n = 11), anorexia (9), dizziness/vertigo (7), lymphadenitis (6), abdominal pain/epigastralgia (5), diarrhea (5), palpitation (5), insomnia (4), limbs numbness (4), drowsiness (4), ecchymosis (3), epistaxis (2), conjunctivitis (1), asthma/bronchitis (1), dysuria (1) and night sweats (1).
SD, standard deviation; GI, gastrointestinal.